Wixela and Breo Ellipta Are Therapeutically Equivalent Products
Both Wixela and Breo Ellipta contain identical active ingredients (fluticasone furoate/vilanterol) at the same doses and are clinically interchangeable—the choice should be based primarily on cost and insurance coverage.
Understanding These Products
Wixela is the generic/authorized generic version of Breo Ellipta. Both deliver:
- Fluticasone furoate (inhaled corticosteroid): 100 mcg or 200 mcg
- Vilanterol (long-acting beta-agonist): 25 mcg
- Once-daily dosing via dry powder inhaler
The FDA-approved indications are identical 1:
- COPD maintenance treatment: 100/25 mcg once daily
- Asthma maintenance (ages 5+):
- Adults ≥18 years: 100/25 or 200/25 mcg once daily
- Ages 12-17 years: 100/25 mcg once daily
- Ages 5-11 years: 50/25 mcg once daily
Clinical Decision Framework
When to Use Either Product
For COPD patients, prescribe the 100/25 mcg strength when 2, 3, 2:
- FEV1 <50% predicted with ≥2 exacerbations per year
- Persistent symptoms despite long-acting bronchodilator monotherapy
- High exacerbation risk (GOLD categories C and D)
For asthma patients, use when 4, 5:
- Step 3-4 therapy is indicated (moderate-to-severe persistent asthma)
- Inadequate control on medium-dose ICS alone
- History of exacerbations requiring systemic corticosteroids
Practical Prescribing Considerations
Choose based on these factors:
Insurance formulary status - This is typically the deciding factor. Wixela (generic) usually has lower copays and better coverage.
Patient out-of-pocket cost - Generic versions can save patients $100-300+ monthly.
Pharmacy availability - Verify your patient's pharmacy stocks the prescribed version.
Device familiarity - If switching from brand to generic (or vice versa), both use the Ellipta device with identical technique, so no retraining needed.
Clinical Efficacy Evidence
The fluticasone furoate/vilanterol combination demonstrates 6, 7, 8:
- Superior lung function improvement versus individual components
- Reduced exacerbation rates compared to vilanterol alone
- Once-daily dosing which improves adherence versus twice-daily alternatives
- Non-inferior to twice-daily fluticasone propionate/salmeterol for pulmonary function
Recent real-world data shows 9, 10:
- Clinically meaningful CAT score improvements (-2.6 units at 12 months)
- Reduction in exacerbation frequency (from 1.4 to 0.2 events/year)
- FEV1 improvement of 93 mL
- Successful switching from twice-daily ICS/LABA combinations
Important Safety Warnings
Both products carry identical risks 1:
- Increased pneumonia risk in COPD patients - Monitor for signs/symptoms
- Not for acute bronchospasm - Patients need separate rescue inhaler
- Never combine with other LABAs - Risk of overdose
- Oral candidiasis - Instruct patients to rinse mouth after use without swallowing
- Adrenal suppression with high doses or prolonged use
- Bone density loss - Consider baseline and periodic DEXA scans
- Ocular effects (cataracts, glaucoma) with long-term use
- Contraindicated in severe milk protein allergy
Special Populations
Hepatic impairment: Use with caution in moderate-to-severe disease; fluticasone exposure increases up to 3-fold. Monitor for corticosteroid side effects 1.
Geriatric patients: No dose adjustment needed, though greater sensitivity possible in some individuals 1.
Pediatric patients: Monitor growth velocity; long-term ICS use may reduce growth 1.
Common Pitfalls to Avoid
Don't prescribe for acute symptoms - This is maintenance therapy only; patients need a separate SABA rescue inhaler 1.
Don't combine with other LABAs - Including formoterol-containing products or salmeterol 1.
Don't use as monotherapy for asthma - The LABA component requires concurrent ICS, which is provided in this combination 1.
Don't forget device technique - Even with the user-friendly Ellipta device, verify proper technique at initiation and follow-up visits.
Don't overlook pneumonia risk in COPD - This is a class effect of ICS therapy; maintain clinical vigilance 2, 7.
Bottom Line Recommendation
Prescribe whichever version (Wixela or Breo Ellipta) provides the best insurance coverage and lowest out-of-pocket cost for your patient. They are bioequivalent products with identical clinical profiles. The therapeutic decision should focus on whether this ICS/LABA combination is appropriate for your patient's disease severity and phenotype, not on brand versus generic selection. For most patients, the generic Wixela will be the more cost-effective choice without sacrificing efficacy or safety.